What Does Sponsor Oversight Mean in ICH-GCP E6 (R3)?

Sponsor oversight has always been a fundamental component of ICH-GCP. It was already reinforced in E6 (R2) with the introduction of Risk-Based Quality Management (RBQM). Oversight responsibilities were clearly addressed in earlier versions of the guideline, notably in relation to CRO oversight, trial management, data handling and record keeping, as well as investigator selection and supervision.

With the release of ICH-GCP E6 (R3), sponsor oversight is further clarified and strengthened, with a strong emphasis on Quality by Design, Risk-Based Quality Management, and continuous oversight. Notably, E6 (R3) now includes a dedicated section on sponsor oversight (Section 3.9). This section explicitly states that sponsors remain accountable for oversight of protocol development and execution, management of protocol deviations, issue escalation processes, and the establishment and functioning of trial committees. The guidance is unequivocal: sponsor oversight must be proactive, systematic, and demonstrable throughout the entire trial lifecycle—it cannot be reactive.

A key principle underpinning sponsor oversight in E6 (R3) is risk proportionality. Oversight activities must be tailored to the specific risks of the clinical trial. Complex study designs—such as gene therapy trials, rare disease studies, or adaptive designs involving specialized dosing or advanced sample processing—require enhanced levels of oversight. Similarly, multisite, multicountry, decentralized, or hybrid trial designs introduce additional variability and operational complexity, making consistent protocol execution more challenging. In these contexts, sponsor oversight should ensure alignment across roles, time points, procedures, and a shared understanding of critical-to-quality factors.

Risk proportionality also applies to CRO and vendor oversight. The intensity and nature of oversight activities should be informed by prior experience with the CRO or vendor, as well as the potential impact of their activities on participant safety, data integrity, and the reliability of trial results.

In practical terms, a low-risk, national, low-interventional clinical trial will require a less intensive oversight approach than a multinational Phase II study. Importantly, E6 (R3) expects sponsors to conduct and document a formal risk assessment at trial initiation and to define the level and scope of oversight based on this assessment.

For those interested in exploring this topic further, I will be presenting on sponsor oversight in May, thanks to WeHive, with a dedicated focus on data governance delivered by Trev Simmons.

The English of this post has been improved thanks to CoPilot.